Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Large ribosomal subunit protein mL63 (MRPL57) is a protein encoded by the nuclear genome that is imported into mitochondria and incorporated into the large 39S mitochondrial ribosomal subunit. It serves as a structural component essential for mitochondrial protein synthesis, playing a role in mitochondrial translation. Unlike prokaryotic ribosomes, mammalian mitochondrial ribosomes have a higher protein-to-rRNA ratio, lack 5S rRNA, and show considerable sequence divergence from their prokaryotic counterparts. MRPL57 is specific to animal mitoribosomes and is conserved across vertebrates. While its disruption or mutation may be linked to mitochondrial disorders, MRPL57 itself is not currently established as a direct therapeutic target, and there are no known drugs that interact with this protein[1][3][10][13].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Large ribosomal subunit protein mL63 (MRPL57).